Non-small cell lung cancer · line 1 · Osimertinib monotherapy (EGFR-mut NSCLC, 1L metastatic OR adjuvant)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-OSIMERTINIB-NSCLC |
| ID | IND-NSCLC-EGFR-MAINT-OSIMERTINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. line_of_therapy: 1 because TKI continuation is part of the 1L pathway (no distinct induction+maintenance phases). Engine activates this indication for any patient on osimertinib 1L beyond first restaging assessment.
Used By
No reverse references found in the YAML corpus.